Cargando…

Remission of lupus nephritis: the trajectory of histological response in successfully treated patients

OBJECTIVE: This study investigated changes in kidney histology over time in patients with lupus nephritis (LN) undergoing immunosuppressive treatment. METHODS: Patients with proliferative±membranous LN were studied. After a diagnostic kidney biopsy (Bx1), patients had protocol biopsy 2 (Bx2) at 9 (6...

Descripción completa

Detalles Bibliográficos
Autores principales: Malvar, Ana, Alberton, Valeria, Lococo, Bruno, Lourenco, Maria, Martinez, Joaquin, Burna, Lucrecia, Besso, Celeste, Navarro, Jordi, Nagaraja, Haikady N, Khatiwada, Aastha, Wolf, Bethany, Rovin, Brad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255076/
https://www.ncbi.nlm.nih.gov/pubmed/37258036
http://dx.doi.org/10.1136/lupus-2023-000932
_version_ 1785056785584881664
author Malvar, Ana
Alberton, Valeria
Lococo, Bruno
Lourenco, Maria
Martinez, Joaquin
Burna, Lucrecia
Besso, Celeste
Navarro, Jordi
Nagaraja, Haikady N
Khatiwada, Aastha
Wolf, Bethany
Rovin, Brad
author_facet Malvar, Ana
Alberton, Valeria
Lococo, Bruno
Lourenco, Maria
Martinez, Joaquin
Burna, Lucrecia
Besso, Celeste
Navarro, Jordi
Nagaraja, Haikady N
Khatiwada, Aastha
Wolf, Bethany
Rovin, Brad
author_sort Malvar, Ana
collection PubMed
description OBJECTIVE: This study investigated changes in kidney histology over time in patients with lupus nephritis (LN) undergoing immunosuppressive treatment. METHODS: Patients with proliferative±membranous LN were studied. After a diagnostic kidney biopsy (Bx1), patients had protocol biopsy 2 (Bx2) at 9 (6–15) months and protocol biopsy 3 (Bx3) at 42 (28–67) months. Kidney histological activity and chronicity indices (AI, CI) were measured. RESULTS: AI declined in a biphasic fashion, falling rapidly between Bx1 and Bx2 and then more slowly between Bx2 and Bx3. Patients were divided into those who achieved histological remission, defined as an AI=0 at Bx3 (group 1), and those with persistent histological activity (AI >0) at Bx3 (group 2). The early decline in AI was 1.6 times greater (95% CI 1.30, 1.91) in group 1 than group 2 (p=0.01). Between Bx2 and Bx3, the AI decline was 2.19-fold greater (95% CI 2.09, 2.29) in group 1 versus group 2 (p=7.34×10(−5)). Individual histological components of the AI resolved at different rates. Inflammatory lesions like glomerular crescents, karyorrhexis and necrosis mostly resolved by Bx2, whereas endocapillary hypercellularity, subendothelial hyaline deposits and interstitial inflammation resolved slowly, accounting for residual histological activity at biopsy 3 in group 2. In contrast, CI increased rapidly, by 0.15 units/month between Bx1 and Bx2, then plateaued. There were no differences in the rate of accumulation of chronic damage between group 1 and group 2. The increase in CI was significantly related to the severity of glomerular crescents (p=0.044), subendothelial hyaline deposits (p=0.002) and interstitial inflammation (p=0.015) at Bx1. CONCLUSIONS: LN histological activity takes months to years to resolve, providing a rationale for the need of long-term, well-tolerated maintenance immunosuppression. Despite responding, LN kidneys accrue chronic damage early during treatment. This finding provides an explanation for the association of chronic progressive kidney disease with recurrent episodes of LN.
format Online
Article
Text
id pubmed-10255076
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-102550762023-06-10 Remission of lupus nephritis: the trajectory of histological response in successfully treated patients Malvar, Ana Alberton, Valeria Lococo, Bruno Lourenco, Maria Martinez, Joaquin Burna, Lucrecia Besso, Celeste Navarro, Jordi Nagaraja, Haikady N Khatiwada, Aastha Wolf, Bethany Rovin, Brad Lupus Sci Med Lupus Nephritis OBJECTIVE: This study investigated changes in kidney histology over time in patients with lupus nephritis (LN) undergoing immunosuppressive treatment. METHODS: Patients with proliferative±membranous LN were studied. After a diagnostic kidney biopsy (Bx1), patients had protocol biopsy 2 (Bx2) at 9 (6–15) months and protocol biopsy 3 (Bx3) at 42 (28–67) months. Kidney histological activity and chronicity indices (AI, CI) were measured. RESULTS: AI declined in a biphasic fashion, falling rapidly between Bx1 and Bx2 and then more slowly between Bx2 and Bx3. Patients were divided into those who achieved histological remission, defined as an AI=0 at Bx3 (group 1), and those with persistent histological activity (AI >0) at Bx3 (group 2). The early decline in AI was 1.6 times greater (95% CI 1.30, 1.91) in group 1 than group 2 (p=0.01). Between Bx2 and Bx3, the AI decline was 2.19-fold greater (95% CI 2.09, 2.29) in group 1 versus group 2 (p=7.34×10(−5)). Individual histological components of the AI resolved at different rates. Inflammatory lesions like glomerular crescents, karyorrhexis and necrosis mostly resolved by Bx2, whereas endocapillary hypercellularity, subendothelial hyaline deposits and interstitial inflammation resolved slowly, accounting for residual histological activity at biopsy 3 in group 2. In contrast, CI increased rapidly, by 0.15 units/month between Bx1 and Bx2, then plateaued. There were no differences in the rate of accumulation of chronic damage between group 1 and group 2. The increase in CI was significantly related to the severity of glomerular crescents (p=0.044), subendothelial hyaline deposits (p=0.002) and interstitial inflammation (p=0.015) at Bx1. CONCLUSIONS: LN histological activity takes months to years to resolve, providing a rationale for the need of long-term, well-tolerated maintenance immunosuppression. Despite responding, LN kidneys accrue chronic damage early during treatment. This finding provides an explanation for the association of chronic progressive kidney disease with recurrent episodes of LN. BMJ Publishing Group 2023-05-31 /pmc/articles/PMC10255076/ /pubmed/37258036 http://dx.doi.org/10.1136/lupus-2023-000932 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Lupus Nephritis
Malvar, Ana
Alberton, Valeria
Lococo, Bruno
Lourenco, Maria
Martinez, Joaquin
Burna, Lucrecia
Besso, Celeste
Navarro, Jordi
Nagaraja, Haikady N
Khatiwada, Aastha
Wolf, Bethany
Rovin, Brad
Remission of lupus nephritis: the trajectory of histological response in successfully treated patients
title Remission of lupus nephritis: the trajectory of histological response in successfully treated patients
title_full Remission of lupus nephritis: the trajectory of histological response in successfully treated patients
title_fullStr Remission of lupus nephritis: the trajectory of histological response in successfully treated patients
title_full_unstemmed Remission of lupus nephritis: the trajectory of histological response in successfully treated patients
title_short Remission of lupus nephritis: the trajectory of histological response in successfully treated patients
title_sort remission of lupus nephritis: the trajectory of histological response in successfully treated patients
topic Lupus Nephritis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255076/
https://www.ncbi.nlm.nih.gov/pubmed/37258036
http://dx.doi.org/10.1136/lupus-2023-000932
work_keys_str_mv AT malvarana remissionoflupusnephritisthetrajectoryofhistologicalresponseinsuccessfullytreatedpatients
AT albertonvaleria remissionoflupusnephritisthetrajectoryofhistologicalresponseinsuccessfullytreatedpatients
AT lococobruno remissionoflupusnephritisthetrajectoryofhistologicalresponseinsuccessfullytreatedpatients
AT lourencomaria remissionoflupusnephritisthetrajectoryofhistologicalresponseinsuccessfullytreatedpatients
AT martinezjoaquin remissionoflupusnephritisthetrajectoryofhistologicalresponseinsuccessfullytreatedpatients
AT burnalucrecia remissionoflupusnephritisthetrajectoryofhistologicalresponseinsuccessfullytreatedpatients
AT bessoceleste remissionoflupusnephritisthetrajectoryofhistologicalresponseinsuccessfullytreatedpatients
AT navarrojordi remissionoflupusnephritisthetrajectoryofhistologicalresponseinsuccessfullytreatedpatients
AT nagarajahaikadyn remissionoflupusnephritisthetrajectoryofhistologicalresponseinsuccessfullytreatedpatients
AT khatiwadaaastha remissionoflupusnephritisthetrajectoryofhistologicalresponseinsuccessfullytreatedpatients
AT wolfbethany remissionoflupusnephritisthetrajectoryofhistologicalresponseinsuccessfullytreatedpatients
AT rovinbrad remissionoflupusnephritisthetrajectoryofhistologicalresponseinsuccessfullytreatedpatients